Nuclear factor of activated T cells in cancer development and treatment

Cancer Letters

Volumn 361, Issue 2, 2015, Pages 174-184

  Shou, Jiawei ^a   Jing, Jing ^b   Xie, Jiansheng ^a   You, Liangkun ^a   Jing, Zhao ^a   Yao, Junlin ^a   Han, Weidong ^a   Pan, Hongming ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Museum of Zhejiang Province   (China)

Author keywords

Calcineurin; Drug resistance; Metastasis; NFAT; Tumor microenvironment

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AFATINIB; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DASATINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PEPTIDE DERIVATIVE; SELUMETINIB; TACROLIMUS; TRAMETINIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT1; TRANSCRIPTION FACTOR NFAT2; TRANSCRIPTION FACTOR NFAT3; TRANSCRIPTION FACTOR NFAT4; TRANSCRIPTION FACTOR NFAT5; UNCLASSIFIED DRUG; VEMURAFENIB; VIVIT; ISOPROTEIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESISTANCE; DRUG SENSITIZATION; HUMAN; LYMPHANGIOGENESIS; MELANOMA; METASTASIS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; SKIN CANCER; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; METABOLISM; NEOPLASMS; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; CARCINOGENESIS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NFATC TRANSCRIPTION FACTORS; PROTEIN ISOFORMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84926115515     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.03.005     Document Type: Review

References (133)

1. Shaw J.P., Utz P.J., Durand D.B., Toole J.J., Emmel E.A., Crabtree G.R. Identification of a putative regulator of early T cell activation genes. Science 1988, 241:202-205.
2. Liu J., Farmer J.D., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66:807-815.
3. Crabtree G.R., Olson E.N. NFAT signaling: choreographing the social lives of cells. Cell 2002, 109(Suppl.):S67-S79.
4. Hogan P.G., Chen L., Nardone J., Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003, 17:2205-2232.
5. 2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol. Rev 2009, 231:241-256.
6. Horsley V., Aliprantis A.O., Polak L., Glimcher L.H., Fuchs E. NFATc1 balances quiescence and proliferation of skin stem cells. Cell 2008, 132:299-310.
7. Jauliac S., Lopez-Rodriguez C., Shaw L.M., Brown L.F., Rao A., Toker A. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat. Cell Biol 2002, 4:540-544.
8. Mancini M., Toker A. NFAT proteins: emerging roles in cancer progression. Nat. Rev. Cancer 2009, 9:810-820.
9. Muller M.R., Rao A. NFAT, immunity and cancer: a transcription factor comes of age. Nat. Rev. Immunol 2010, 10:645-656.
10. Medyouf H., Ghysdael J. The calcineurin/NFAT signaling pathway: a novel therapeutic target in leukemia and solid tumors. Cell Cycle 2008, 7:297-303.
11. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
12. Chuvpilo S., Avots A., Berberich-Siebelt F., Glockner J., Fischer C., Kerstan A., et al. Multiple NF-ATc isoforms with individual transcriptional properties are synthesized in T lymphocytes. J. Immunol 1999, 162:7294-7301.
13. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol 2005, 5:472-484.
14. Lopez-Rodriguez C., Aramburu J., Rakeman A.S., Rao A. NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:7214-7219.
15. Luo C., Shaw K.T., Raghavan A., Aramburu J., Garcia-Cozar F., Perrino B.A., et al. Interaction of calcineurin with a domain of the transcription factor NFAT1 that controls nuclear import. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:8907-8912.
16. Jain J., McCaffrey P.G., Valge-Archer V.E., Rao A. Nuclear factor of activated T cells contains Fos and Jun. Nature 1992, 356:801-804.
17. Chen L., Glover J.N., Hogan P.G., Rao A., Harrison S.C. Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA. Nature 1998, 392:42-48.
18. Wu Y., Borde M., Heissmeyer V., Feuerer M., Lapan A.D., Stroud J.C., et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006, 126:375-387.
19. Okamura H., Aramburu J., Garcia-Rodriguez C., Viola J.P., Raghavan A., Tahiliani M., et al. Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol. Cell 2000, 6:539-550.
20. Hogan P.G., Lewis R.S., Rao A. Molecular basis of calcium signaling in lymphocytes: STIM and ORAI. Annu. Rev. Immunol 2010, 28:491-533.
21. Penna A., Demuro A., Yeromin A.V., Zhang S.L., Safrina O., Parker I., et al. The CRAC channel consists of a tetramer formed by Stim-induced dimerization of Orai dimers. Nature 2008, 456:116-120.
22. Cahalan M.D. STIMulating store-operated Ca(2+) entry. Nat. Cell Biol 2009, 11:669-677.
23. 2+ entry and NFAT activation in lymphocytes. Cell Calcium 2007, 42:145-156.
24. Prevarskaya N., Skryma R., Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat. Rev. Cancer 2011, 11:609-618.
25. 2+ signaling. Cold Spring Harb. Perspect. Biol 2010, 2:a003962.
26. Klee C.B., Ren H., Wang X. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J. Biol. Chem 1998, 273:13367-13370.
27. Stemmer P.M., Klee C.B. Dual calcium ion regulation of calcineurin by calmodulin and calcineurin B. Biochemistry 1994, 33:6859-6866.
28. Takeuchi K., Roehrl M.H., Sun Z.Y., Wagner G. Structure of the calcineurin-NFAT complex: defining a T cell activation switch using solution NMR and crystal coordinates. Structure 2007, 15:587-597.
29. Fuentes J.J., Genesca L., Kingsbury T.J., Cunningham K.W., Perez-Riba M., Estivill X., et al. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum. Mol. Genet 2000, 9:1681-1690.
30. Sun L., Youn H.D., Loh C., Stolow M., He W., Liu J.O. Cabin 1, a negative regulator for calcineurin signaling in T lymphocytes. Immunity 1998, 8:703-711.
31. Klauck T.M., Faux M.C., Labudda K., Langeberg L.K., Jaken S., Scott J.D. Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein. Science 1996, 271:1589-1592.
32. Hasle H., Clemmensen I.H., Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000, 355:165-169.
33. Baek K.H., Zaslavsky A., Lynch R.C., Britt C., Okada Y., Siarey R.J., et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009, 459:1126-1130.
34. Beals C.R., Sheridan C.M., Turck C.W., Gardner P., Crabtree G.R. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 1997, 275:1930-1934.
35. Gwack Y., Sharma S., Nardone J., Tanasa B., Iuga A., Srikanth S., et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 2006, 441:646-650.
36. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
37. Singh S.K., Baumgart S., Singh G., Konig A.O., Reutlinger K., Hofbauer L.C., et al. Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid. J. Biol. Chem 2011, 286:28761-28771.
38. Yoeli-Lerner M., Yiu G.K., Rabinovitz I., Erhardt P., Jauliac S., Toker A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol. Cell 2005, 20:539-550.
39. Chow C.W., Dong C., Flavell R.A., Davis R.J. c-Jun NH(2)-terminal kinase inhibits targeting of the protein phosphatase calcineurin to NFATc1. Mol. Cell. Biol 2000, 20:5227-5234.
40. Yang T.T., Xiong Q., Enslen H., Davis R.J., Chow C.W. Phosphorylation of NFATc4 by p38 mitogen-activated protein kinases. Mol. Cell. Biol 2002, 22:3892-3904.
41. Okamura H., Garcia-Rodriguez C., Martinson H., Qin J., Virshup D.M., Rao A. A conserved docking motif for CK1 binding controls the nuclear localization of NFAT1. Mol. Cell. Biol 2004, 24:4184-4195.
42. de Gregorio R., Iniguez M.A., Fresno M., Alemany S. Cot kinase induces cyclooxygenase-2 expression in T cells through activation of the nuclear factor of activated T cells. J. Biol. Chem 2001, 276:27003-27009.
43. Gomez-Casero E., San-Antonio B., Iniguez M.A., Fresno M. Cot/Tpl2 and PKCzeta cooperate in the regulation of the transcriptional activity of NFATc2 through the phosphorylation of its amino-terminal domain. Cell. Signal 2007, 19:1652-1661.
44. Vazquez-Cedeira M., Lazo P.A. Human VRK2 (vaccinia-related kinase 2) modulates tumor cell invasion by hyperactivation of NFAT1 and expression of cyclooxygenase-2. J. Biol. Chem 2012, 287:42739-42750.
45. Wu W., Misra R.S., Russell J.Q., Flavell R.A., Rincon M., Budd R.C. Proteolytic regulation of nuclear factor of activated T (NFAT) c2 cells and NFAT activity by caspase-3. J. Biol. Chem 2006, 281:10682-10690.
46. Olabisi O.A., Soto-Nieves N., Nieves E., Yang T.T., Yang X., Yu R.Y., et al. Regulation of transcription factor NFAT by ADP-ribosylation. Mol. Cell. Biol 2008, 28:2860-2871.
47. Valdor R., Schreiber V., Saenz L., Martinez T., Munoz-Suano A., Dominguez-Villar M., et al. Regulation of NFAT by poly(ADP-ribose) polymerase activity in T cells. Mol. Immunol 2008, 45:1863-1871.
48. Nayak A., Glockner-Pagel J., Vaeth M., Schumann J.E., Buttmann M., Bopp T., et al. Sumoylation of the transcription factor NFATc1 leads to its subnuclear relocalization and interleukin-2 repression by histone deacetylase. J. Biol. Chem 2009, 284:10935-10946.
49. Robbs B.K., Cruz A.L., Werneck M.B., Mognol G.P., Viola J.P. Dual roles for NFAT transcription factor genes as oncogenes and tumor suppressors. Mol. Cell. Biol 2008, 28:7168-7181.
50. Lu H., Shi X., Costa M., Huang C. Carcinogenic effect of nickel compounds. Mol. Cell. Biochem 2005, 279:45-67.
51. Li J., Huang B., Shi X., Castranova V., Vallyathan V., Huang C. Involvement of hydrogen peroxide in asbestos-induced NFAT activation. Mol. Cell. Biochem 2002, 234-235:161-168.
52. Musson R.E., Mullenders L.H., Smit N.P. Effects of arsenite and UVA-1 radiation on calcineurin signaling. Mutat. Res 2012, 735:32-38.
53. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397:530-534.
54. Muellenhoff M.W., Koo J.Y. Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology. J. Dermatolog. Treat 2012, 23:290-304.
55. Yarosh D.B., Pena A.V., Nay S.L., Canning M.T., Brown D.A. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J. Invest. Dermatol 2005, 125:1020-1025.
56. Maziere C., Morliere P., Louandre C., Conte M.A., Gomilla C., Santus R., et al. Low UVA doses activate the transcription factor NFAT in human fibroblasts by a calcium-calcineurin pathway. Free Radic. Biol. Med 2005, 39:1629-1637.
57. Neal J.W., Clipstone N.A. A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. J. Biol. Chem 2003, 278:17246-17254.
58. 2+/calcineurin signaling pathway. EMBO J. 2006, 25:3714-3724.
59. Singh G., Singh S.K., Konig A., Reutlinger K., Nye M.D., Adhikary T., et al. Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation. J. Biol. Chem 2010, 285:27241-27250.
60. Baksh S., Widlund H.R., Frazer-Abel A.A., Du J., Fosmire S., Fisher D.E., et al. NFATc2-mediated repression of cyclin-dependent kinase 4 expression. Mol. Cell 2002, 10:1071-1081.
61. Carvalho L.D., Teixeira L.K., Carrossini N., Caldeira A.T., Ansel K.M., Rao A., et al. The NFAT1 transcription factor is a repressor of cyclin A2 gene expression. Cell Cycle 2007, 6:1789-1795.
62. Ranger A.M., Oukka M., Rengarajan J., Glimcher L.H. Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. Immunity 1998, 9:627-635.
63. Oukka M., Ho I.C., de la Brousse F.C., Hoey T., Grusby M.J., Glimcher L.H. The transcription factor NFAT4 is involved in the generation and survival of T cells. Immunity 1998, 9:295-304.
64. Zhang X., Zhang Z., Cheng J., Li M., Wang W., Xu W., et al. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53. J. Biol. Chem 2012, 287:30468-30476.
65. Baumgart S., Glesel E., Singh G., Chen N.M., Reutlinger K., Zhang J., et al. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology 2012, 142:388-398.e1-7.
66. Tripathi P., Wang Y., Coussens M., Manda K.R., Casey A.M., Lin C., et al. Activation of NFAT signaling establishes a tumorigenic microenvironment through cell autonomous and non-cell autonomous mechanisms. Oncogene 2014, 33:1840-1849.
67. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
68. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest 2009, 119:1420-1428.
69. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
70. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
71. Mercurio A.M., Rabinovitz I. Towards a mechanistic understanding of tumor invasion - lessons from the alpha6beta 4 integrin. Semin. Cancer Biol 2001, 11:129-141.
72. Liu J.F., Zhao S.H., Wu S.S. Depleting NFAT1 expression inhibits the ability of invasion and migration of human lung cancer cells. Cancer Cell Int 2013, 13:1-7.
73. Chen Z.L., Zhao S.H., Wang Z., Qiu B., Li B.Z., Zhou F., et al. Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer. Chin. J. Cancer 2011, 30:62-68.
74. Yiu G.K., Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J. Biol. Chem 2006, 281:12210-12217.
75. Chen M., O'Connor K.L. Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells. Oncogene 2005, 24:5125-5130.
76. Yiu G.K., Kaunisto A., Chin Y.R., Toker A. NFAT promotes carcinoma invasive migration through glypican-6. Biochem. J. 2011, 440:157-166.
77. Foldynova-Trantirkova S., Sekyrova P., Tmejova K., Brumovska E., Bernatik O., Blankenfeldt W., et al. Breast cancer-specific mutations in CK1epsilon inhibit Wnt/beta-catenin and activate the Wnt/Rac1/JNK and NFAT pathways to decrease cell adhesion and promote cell migration. Breast Cancer Res 2010, 12:1-14.
78. Mott J.D., Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol 2004, 16:558-564.
79. Saygili E., Rana O.R., Meyer C., Gemein C., Andrzejewski M.G., Ludwig A., et al. The angiotensin-calcineurin-NFAT pathway mediates stretch-induced up-regulation of matrix metalloproteinases-2/-9 in atrial myocytes. Basic Res. Cardiol 2009, 104:435-448.
80. Alfonso-Jaume M.A., Mahimkar R., Lovett D.H. Co-operative interactions between NFAT (nuclear factor of activated T cells) c1 and the zinc finger transcription factors Sp1/Sp3 and Egr-1 regulate MT1-MMP (membrane type 1 matrix metalloproteinase) transcription by glomerular mesangial cells. Biochem. J. 2004, 380:735-747.
81. Neria F., del Carmen Serrano-Perez M., Velasco P., Urso K., Tranque P., Cano E. NFATc3 promotes Ca(2+) -dependent MMP3 expression in astroglial cells. Glia 2013, 61:1052-1066.
82. Tie X., Han S., Meng L., Wang Y., Wu A. NFAT1 is highly expressed in, and regulates the invasion of, glioblastoma multiforme cells. PLoS ONE 2013, 8:e66008.
83. Velupillai P., Sung C.K., Tian Y., Dahl J., Carroll J., Bronson R., et al. Polyoma virus-induced osteosarcomas in inbred strains of mice: host determinants of metastasis. PLoS Pathog 2010, 6:e1000733.
84. Fougere M., Gaudineau B., Barbier J., Guaddachi F., Feugeas J.P., Auboeuf D., et al. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene. Oncogene 2010, 29:2292-2301.
85. Graef I.A., Chen F., Chen L., Kuo A., Crabtree G.R. Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 2001, 105:863-875.
86. Maillet M., Davis J., Auger-Messier M., York A., Osinska H., Piquereau J., et al. Heart-specific deletion of CnB1 reveals multiple mechanisms whereby calcineurin regulates cardiac growth and function. J. Biol. Chem 2010, 285:6716-6724.
87. Courtwright A., Siamakpour-Reihani S., Arbiser J.L., Banet N., Hilliard E., Fried L., et al. Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. Cancer Res 2009, 69:4621-4628.
88. Siamakpour-Reihani S., Caster J., Bandhu Nepal D., Courtwright A., Hilliard E., Usary J., et al. The role of calcineurin/NFAT in SFRP2 induced angiogenesis - a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus. PLoS ONE 2011, 6:e20412.
89. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med 2003, 9:669-676.
90. Hernandez G.L., Volpert O.V., Iniguez M.A., Lorenzo E., Martinez-Martinez S., Grau R., et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp. Med 2001, 193:607-620.
91. Zaichuk T.A., Shroff E.H., Emmanuel R., Filleur S., Nelius T., Volpert O.V. Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J. Exp. Med 2004, 199:1513-1522.
92. Armesilla A.L., Lorenzo E., Gomez del Arco P., Martinez-Martinez S., Alfranca A., Redondo J.M. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol. Cell. Biol 1999, 19:2032-2043.
93. Jinnin M., Medici D., Park L., Limaye N., Liu Y., Boscolo E., et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat. Med 2008, 14:1236-1246.
94. Onimaru M., Yonemitsu Y., Fujii T., Tanii M., Nakano T., Nakagawa K., et al. VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B. Am. J. Physiol. Heart Circ. Physiol 2009, 297:1685-1696.
95. Achen M.G., Stacker S.A. Molecular control of lymphatic metastasis. Ann. N. Y. Acad. Sci 2008, 1131:225-234.
96. Liu J., Liu C., Qiu L., Li J., Zhang P., Sun Y. Overexpression of both platelet-derived growth factor-BB and vascular endothelial growth factor-C and its association with lymphangiogenesis in primary human non-small cell lung cancer. Diagn. Pathol 2014, 9:1-8.
97. Kulkarni R.M., Greenberg J.M., Akeson A.L. NFATc1 regulates lymphatic endothelial development. Mech. Dev 2009, 126:350-365.
98. Mosieniak G., Figiel I., Kaminska B. Cyclosporin A, an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor. J. Neurochem 1997, 68:1142-1149.
99. Pham L.V., Tamayo A.T., Yoshimura L.C., Lin-Lee Y.C., Ford R.J. Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood 2005, 106:3940-3947.
100. Gopinath S., Vanamala S.K., Gujrati M., Klopfenstein J.D., Dinh D.H., Rao J.S. Doxorubicin-mediated apoptosis in glioma cells requires NFAT3. Cell. Mol. Life Sci 2009, 66:3967-3978.
101. Alvarez S., Blanco A., Fresno M., Munoz-Fernandez M.A. TNF-alpha contributes to caspase-3 independent apoptosis in neuroblastoma cells: role of NFAT. PLoS ONE 2011, 6:e16100.
102. Robbs B.K., Lucena P.I., Viola J.P. The transcription factor NFAT1 induces apoptosis through cooperation with Ras/Raf/MEK/ERK pathway and upregulation of TNF-alpha expression. Biochim. Biophys. Acta 1833, 2013:2016-2028.
103. Vogler M., Butterworth M., Majid A., Walewska R.J., Sun X.M., Dyer M.J., et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009, 113:4403-4413.
104. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med 2002, 346:645-652.
105. 2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010, 18:74-87.
106. Griesmann H., Ripka S., Pralle M., Ellenrieder V., Baumgart S., Buchholz M., et al. WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. Neoplasia 2013, 15:11-22.
107. Pao W., Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 2010, 10:760-774.
108. Harada D., Takigawa N., Kiura K. The role of STAT3 in non-small cell lung cancer. Cancers (Basel) 2014, 6:708-722.
109. Lee H.J., Zhuang G., Cao Y., Du P., Kim H.J., Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014, 26:207-221.
110. Lagunas L., Clipstone N.A. Deregulated NFATc1 activity transforms murine fibroblasts via an autocrine growth factor-mediated Stat3-dependent pathway. J. Cell. Biochem 2009, 108:237-248.
111. Kundumani-Sridharan V., Van Quyen D., Subramani J., Singh N.K., Chin Y.E., Rao G.N. Novel interactions between NFATc1 (Nuclear Factor of Activated T cells c1) and STAT-3 (Signal Transducer and Activator of Transcription-3) mediate G protein-coupled receptor agonist, thrombin-induced biphasic expression of cyclin D1, with first phase influencing cell migration and second phase directing cell proliferation. J. Biol. Chem 2012, 287:22463-22482.
112. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med 2011, 364:2507-2516.
113. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med 2012, 367:107-114.
114. Perotti V., Baldassari P., Bersani I., Molla A., Vegetti C., Tassi E., et al. NFATc2 is a potential therapeutic target in human melanoma. J. Invest. Dermatol 2012, 132:2652-2660.
115. Flockhart R.J., Armstrong J.L., Reynolds N.J., Lovat P.E. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. Br. J. Cancer 2009, 101:1448-1455.
116. Spreafico A., Tentler J.J., Pitts T.M., Tan A.C., Gregory M.A., Arcaroli J.J., et al. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin. Cancer Res 2013, 19:4149-4162.
117. Mathot L., Stenninger J. Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding. Cancer Sci 2012, 103:626-631.
118. Albini A., Sporn M.B. The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer 2007, 7:139-147.
119. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
120. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
121. Karnoub A.E., Weinberg R.A. Chemokine networks and breast cancer metastasis. Breast Dis 2006, 26:75-85.
122. Wyckoff J., Wang W., Lin E.Y., Wang Y., Pixley F., Stanley E.R., et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004, 64:7022-7029.
123. Minami T., Jiang S., Schadler K., Suehiro J., Osawa T., Oike Y., et al. The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases. Cell Rep 2013, 4:709-723.
124. Werneck M.B., Vieira-de-Abreu A., Chammas R., Viola J.P. NFAT1 transcription factor is central in the regulation of tissue microenvironment for tumor metastasis. Cancer Immunol. Immunother 2011, 60:537-546.
125. Abe B.T., Shin D.S., Mocholi E., Macian F. NFAT1 supports tumor-induced anergy of CD4(+) T cells. Cancer Res 2012, 72:4642-4651.
126. Martinez-Martinez S., Redondo J.M. Inhibitors of the calcineurin/NFAT pathway. Curr. Med. Chem 2004, 11:997-1007.
127. Aramburu J., Yaffe M.B., Lopez-Rodriguez C., Cantley L.C., Hogan P.G., Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 1999, 285:2129-2133.
128. Noguchi H., Matsushita M., Okitsu T., Moriwaki A., Tomizawa K., Kang S., et al. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat. Med 2004, 10:305-309.
129. Rezzani R. Cyclosporine A and adverse effects on organs: histochemical studies. Prog. Histochem. Cytochem 2004, 39:85-128.
130. Dantal J., Soulillou J.P. Immunosuppressive drugs and the risk of cancer after organ transplantation. N. Engl. J. Med 2005, 352:1371-1373.
131. Sieber M., Baumgrass R. Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?. Cell Commun. Signal 2009, 7:1-19.
132. Dai W., Wang F., He L., Lin C., Wu S., Chen P., et al. Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: partial mediation by the transcription factor NFAT. Mol. Carcinog 2013, Epub ahead of print.
133. Yang Q.F., Dalgard C.L., Eidelman O., Jozwik C., Pollard B.S., Srivastava M., et al. Digitoxin induces apoptosis in cancer cells by inhibiting nuclear factor of activated T-cells-driven c-MYC expression. J. Carcinog 2013, 12:1-24.